Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Atrion Reports First Quarter Results

May 8, 2019

ALLEN, Texas, May 08, 2019 (GLOBE NEWSWIRE) -- Atrion Corporation (Nasdaq - ATRI) today announced revenues for the quarter ended March 31, 2019 were $41.6 million compared with $39.4 million in the same period in 2018. Net income in the current-year quarter totaled $9.4 million compared to $8.5 million in last year’s first quarter, with diluted earnings per share for the first quarter of 2019 at $5.07 compared to $4.57 in the first quarter of 2018.

Commenting on the Company’s results for the first quarter of 2019 compared to the same period last year, David A. Battat, President & CEO, said, “We are pleased with the 6% increase in revenues and the 11% increase in both net income and diluted earnings per share. These results were achieved despite an 18% decline in Ophthalmology revenues. The discontinuation of one Ophthalmology product resulted in a decline of over $500,000 in operating income from the prior-year quarter.” Mr. Battat continued, “Net income and diluted EPS were favorably impacted by the increase in revenues, as well as the appreciation in the mark-to-market valuation of our investment portfolio and tax credits for our international business, which accounted for 35% of our revenues for the quarter.” Mr. Battat added, “In the just-ended quarter, we continued to generate significant free cash flow, adding $6.8 million to our cash and short and long term investments and bringing that total to $96.3 million as of March 31, 2019.” Mr. Battat stated, “To support our longer term growth, we will be investing in additional manufacturing space for our Florida and Alabama facilities. The $40 million anticipated cost of these expansions, to be incurred over the next few years, will be in addition to our annual investments in machinery and tooling. Completion of these projects will significantly enhance our efficiency and add about 50% more manufacturing capacity.”

Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially. Such statements include, but are not limited to, Atrion’s expectations regarding investments in additional manufacturing space, including the cost and the benefits to be derived therefrom. Words such as “expects,” “believes,” “anticipates,” “intends,” “should”, “plans,” “will” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements involve risks and uncertainties. The following are some of the factors that could cause actual results or future events to differ materially from those expressed in or underlying our forward-looking statements: changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; the Company’s ability to protect its intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; and the loss of, or any material reduction in sales to, any significant customers.. The foregoing list of factors is not exclusive, and other factors are set forth in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.


Jeffery StricklandVice President and Chief Financial Officer(972) 390-9800

ATRION CORPORATION CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data) (Unaudited) Three Months Ended March 31, 2019 2018 - -------- - -------- Revenues $ 41,614 $ 39,401 Cost of goods sold 22,911 20,450 - ------ - - ------ - Gross profit 18,703 18,951 Operating expenses 7,666 7,585 - ------ - - ------ - Operating income 11,037 11,366 Interest and dividend income 582 313 Other investment income (loss) 211 (772 ) Income before income taxes 11,830 10,907 Income tax provision (2,392 ) (2,420 ) - ------ - - ------ - Net income 9,438 8,487 - ------ - - ------ - Income per basic share $ 5.09 $ 4.58 Weighted average basic shares outstanding 1,853 1,852 - ------ - - ------ - Income per diluted share $ 5.07 $ 4.57 - ------ - - ------ - Weighted average diluted shares outstanding 1,862 1,856 - ------ - - ------ -

ATRION CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands) Mar. 31, Dec. 31, ASSETS 2019 2018 --------- --------- (Unaudited ) Current assets: Cash and cash equivalents $ 44,043 $ 58,753 Short-term investments 24,779 9,684 - ------- Total cash and short-term investments 68,822 68,437 Accounts receivable 21,240 17,014 Inventories 32,801 33,572 Prepaid expenses and other 1,803 3,242 Total current assets 124,666 122,265 Long-term investments 27,466 21,048 Property, plant and equipment, net 75,940 74,893 Other assets 12,946 13,010 - ------- - ------- $ 241,018 $ 231,216 - ------- - ------- LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities 11,013 10,220 Line of credit -- -- Other non-current liabilities 11,922 10,229 Stockholders’ equity 218,083 210,767 - ------- - ------- $ 241,018 $ 231,216 - ------- - -------